Scroll

lapatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	1548	231277-92-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lapatinib tosilate hydrate lapatinib tosilate lapatinib GW 572016X tyverb lapatinib ditosylate GW572016F lapatinib ditosilate lapatinib ditosilate hydrate lapatinib ditosylate hydrate	A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2. Molecular weight: 581.06 Formula: C29H26ClFN4O4S CLOGP: 5.82 LIPINSKI: 2 HAC: 8 HDO: 2 TPSA: 106.35 ALOGS: -4.42 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lapatinib tosilate hydrate
lapatinib tosilate
lapatinib
GW 572016X
tyverb
lapatinib ditosylate
GW572016F
lapatinib ditosilate
lapatinib ditosilate hydrate
lapatinib ditosylate hydrate

A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.

Molecular weight: 581.06
Formula: C29H26ClFN4O4S
CLOGP: 5.82
LIPINSKI: 2
HAC: 8
HDO: 2
TPSA: 106.35
ALOGS: -4.42
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.25	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	30.73 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
June 10, 2008	EMA
March 13, 2007	FDA	NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome	1854.14	20.69	574	23090	22441	63442917
Diarrhoea	1520.82	20.69	1572	22092	713794	62751564
Disease progression	856.30	20.69	545	23119	122213	63343145
Metastases to central nervous system	646.51	20.69	226	23438	12879	63452479
Malignant neoplasm progression	394.13	20.69	290	23374	81831	63383527
Neutropenia	320.31	20.69	359	23305	174646	63290712
Paronychia	309.36	20.69	105	23559	5460	63459898
Metastases to liver	273.12	20.69	146	23518	23493	63441865
Metastases to lung	266.05	20.69	118	23546	12632	63452726
Dehydration	254.75	20.69	318	23346	173036	63292322

Showing 1 to 10 of 134 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Duodenal ulcer perforation	53.49	36.55	12	1095	1620	34954204
Diarrhoea	43.46	36.55	57	1050	389855	34565969
Metastases to lung	36.58	36.55	13	1094	9307	34946517

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome	1166.08	20.25	381	15894	32753	79695360
Diarrhoea	1036.46	20.25	1066	15209	879423	78848690
Disease progression	549.36	20.25	384	15891	183978	79544135
Metastases to central nervous system	405.64	20.25	145	16130	16230	79711883
Malignant neoplasm progression	298.24	20.25	236	16039	135754	79592359
Metastases to lung	240.11	20.25	102	16173	18061	79710052
Metastases to liver	208.47	20.25	106	16169	28208	79699905
Dehydration	175.79	20.25	234	16041	247953	79480160
Paronychia	174.06	20.25	64	16211	7744	79720369
Breast cancer metastatic	164.43	20.25	63	16212	8539	79719574

Showing 1 to 10 of 85 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01EH01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
HER2-positive carcinoma of breast	indication	427685000
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Hepatic failure	contraindication	59927004
Interstitial pneumonia	contraindication	64667001
Left heart failure	contraindication	85232009
Prolonged QT interval	contraindication	111975006
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Drug-induced hepatitis	contraindication	235876009

Showing 1 to 10 of 14 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.62	Basic
pKa2	4.99	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	9.04	CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	8.15	CHEMBL	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		IC50	5.07	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		IC50	4.64	CHEMBL
Solute carrier organic anion transporter family member 1B1	Transporter	Q9Y6L6	SO1B1_HUMAN				WOMBAT-PK
Cyclin-dependent kinase 2	Kinase	P24941	CDK2_HUMAN		IC50	4.96	CHEMBL
Insulin receptor	Kinase	P06213	INSR_HUMAN	AGONIST	IC50	4.77	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN		Kd	7.27	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	5.59	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5.44	CHEMBL

Showing 1 to 10 of 20 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
012020	NDDF
012022	NDDF
0VUA21238F	UNII
208908	PUBCHEM_CID
339254	MMSL
388082-78-8	SECONDARY_CAS_RN
4026029	VUID
4026029	VANDF
425466009	SNOMEDCT_US
425820005	SNOMEDCT_US

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lapatinib	Human Prescription Drug Label	1	68180-801	TABLET	250 mg	ORAL	ANDA	28 sections
Lapatinib	Human Prescription Drug Label	1	68180-801	TABLET	250 mg	ORAL	ANDA	28 sections
TYKERB	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0671	TABLET	250 mg	ORAL	NDA	34 sections
TYKERB	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0671	TABLET	250 mg	ORAL	NDA	34 sections
TYKERB	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0671	TABLET	250 mg	ORAL	NDA	34 sections

Showing 1 to 5 of 5 entries

Previous1Next